In fact, it has been reported that potent kinase inhibitors of CDK4/6 with the goal of slowing tumor growth have been observed as a secondary unanticipated effect: exhibited a change in the TME, and increased sensitivity to ICI relative to controls in certain tumors including breast cancer, pancreatic cancer, and melanoma in preclinical studies [33]. Here, CDK4 is linked to melanoma.